ABSTRACT We carried out cytogenetic studies of four Chinese hamster, mouse, and human cell lines selected for high levels of resistance (500-to 4,000-fold) to vincristine (VCR) by a multistep selection procedure. All cells examined contained gene amplification-associated metaphase chromosome abnormalities, either homogeneously staining regions (HSRs), abnormally banding regions (ABRs), or double-minute chromosomes (DMs); control actinomycin D-and daunorubicin-resistant hamster lines did not exhibit this type of chromosomal abnormality. VCR-resistant Chinese hamster sublines exhibited both increased synthesis of the protein V19 (Mr 19,000; pl = 5.7) and increased concentrations of V19 polysomal mRNA. When VCR-resistant cells were grown in drug-free medium, level of resistance, synthesis of V19, and amount of V19 mRNA declined in parallel with mean length of the HSR or mean number of DMs per cell. Cross-resistance studies indicate that VCR-resistant cells have increased resistance both to antimitotic agents and to a wide variety of agents unrelated to VCR in chemical structure and/or mechanism of action. Our studies of tubulin synthesis in Chinese hamster cells indicate no overproduction of tubulin or presence of a mutant tubulin species. Comparison with antifolate-resistant Chinese hamster cells known to contain amplified dihydrofolate reductase genes localized to HSRs or ABRs strongly suggests that the HSRs, ABRs, or DMs of the Vinca alkaloid-resistant sublines likewise represent cytological manifestations of specifically amplified genes, possibly encoding V19, involved in development of resistance to VCR.
high levels of target enzyme dihydrofolate reductase (DHFR) (1, 2) . It has been demonstrated that increased activity of DHFR in resistant sublines derived in cell culture by progressive increases in selective drug concentration is due to an increased rate of biosynthesis of the enzyme (3) (4) (5) , accompanied by increase in cellular concentration of DHFR-specific mRNA (6) (7) (8) . The basis of these overproduction phenomena was found to be selective amplification of DHFR-encoding genes (9, 10) . Moreover, in antifolate-resistant, HSR-containing hamster and mouse cells, HSRs are sites of amplified DHFR genes (1 l-14) .
Another distinctive chromosomal abnormality indicative of DNA sequence amplification is the double-minute chromosome (DM) (15) (16) (17) . DMs are small, paired extrachromo-somal chromatin bodies that appear to lack a centromere. Variable in both number and size, DMs have been found in various methotrexate-resistant mouse ( 15, 18, 19) and human (20, 21) 
MATERIALS AND METHODS

Derivation of Cell Lines and Clones: Cell lines DC-3F/VCRd
and DC-3F/VCRm are independently derived VCR-resistant sublines of the CHL cell line, DC-3F (31). Both were selected by exposure to stepwise (2-2.5-fold) increases in VCR concentration and are maintained in l0 ug/ml drug. Clonal sublines DC-3F/VCRd-I and DC-3F/VCRd-5 were isolated from DC-3F/VCRd cells inoculated into Falcon Microtest II plates in 5 ug/ml VCR. After initial characterizations, both clones were transferred to drug-free medium, designated DC-3F/VCRd-I-U and DC-3F/VCRd-5-U, and grown in absence of drug for 21/2 yr. Clone DC-3F/VCRd-5 was also further selected with higher concentrations of VCR; the resulting, highly resistant subline designated DC-3F/VCRd-5L grows in 50 #g/ml VCR. The actinomycin D-and daunorubicin-resistant CHL sublines DC-3F/AD X (2,450-fold resistant) and DC-3F/DM XX (883-fold resistant) have been described (31, 32) . DC-3F/AD XC (50.000-fold resistant) was selected from DC-3F/ADX cells by multistep increases in concentration of actinomycin D from 10 to 100 ug/ml. The drugsensitive mouse tumor line, MAZ, was clonally isolated from cells established in vitro from a hydrocarbon-induced tumor ofa C57BL/6 mouse (22) . Selection with VCR yielded the resistant cell line, MAZ/VCR, now maintained at 20 ~g/ml drug. The VCR-resistant human neuroblastoma cell line SH-SY5Y/ VCR was selected from SH-SY5Y, a clonal subline of the neuroblastoma line SK-N-SH (33, 34) . Revertant sublines MAZ/VCR-U and SH-SY5Y/VCR-U were initiated from drug-treated sublines without prior cloning and grown in drug-free medium for 14 and 8 mo, respectively. VCR-resistant cell lines are listed in Table I .
Cell Culture Techniques: Chinese hamster and mouse cells are cultured either in Eagle's minimum essential medium or in a 1:1 mixture of that medium and Ham's FI2 medium, supplemented with 5 or 10% fetal bovine serum, 100 IU/ml penicillin, and 100 #g/ml streptomycin. Drugresistant sublines are routinely maintained in presence of drug but are grown in drug-free medium for 10-15 d (CHL cells) or 2-4 d (MAZ cells) before experimentation. Procedures for determination of drug sensitivity have been described (31) . To obtain EDs0 (half-maximal effective dose) values, we carried out two or three independent dose-response assays for each cell line. Modifications of experimental conditions for the more slowly growing human neuroblastoma cells include increase in serum concentration to 15% and a longer period of growth (6 d) in dose-response assays. VCR was generously provided by Eli Lilly and Co.
Chromosomal Analyses: Cells for karyotype studies were prepared and stained by standard procedures (35) modified from the method of Seabright (36) , with or without pretreatment with 0.001-5 t~g/ml Colcemid. Preparations were stained both by trypsin-Giemsa techniques for chromosome identification and by conventional methods to better assess DM size and number. HSR length was determined from photographs of 15-20 metaphase plates per sample, as described earlier (35) . Chinese hamster chromosome nomenclature has been modified from earlier, published analyses (22) as suggested by Ray and Mohandas (37) . Human chromosome nomenclature follows the conventions of ISCN (1978): An International System for Human Cytogenetic Nomenclature (1978) (38) .
Chromosomal DNA replication patterns were determined as previously described ( 1, 2).
Protein Analyses: Cells were grown in methionine-deficient growth medium containing 10/~Ci/ml [35S]methionine (New England Nuclear, Boston, MA) for 4 h, except where noted, then harvested and lysed by sonication as previously described (24) unles s otherwise stated. Two-dimensional (2D) gel electrophoresis was carried out according to the methods of O'Farrell et al. (39) . The completed 5-13% acrylamide gradient slab gels (0.75 x 14 x 35 cm) were treated with sodium salicylate (Aldrich Chemical Co., Inc., Milwaukee, WI) (40) , dried, and exposed at -70"C with X-OMAT AR film (Eastman Kodak Co., Rochester, NY). The 2D gels are oriented with basic proteins at left and acidic proteins at right, in each panel. The acid side of the 2D gels in this report is on the right.
Microtubules from radiolabeled DC-3F and DC-3F/VCRd-5 cells were assembled through one cycle of polymerization as described by Shelanski et al. (41) . The microtubule pellets were solubilized in O'Farrell buffer (39) before 2D gel analysis. In some experiments, cells were treated with 5 ~g/ml colchicine to stop de novo synthesis of tubulin, then lysed with detergent (42) . Absence of (19, 47, 48) .
Control MAZ cells contain a low number of DMs; however, both the number of DMs and the frequency of DM-containing cells are greatly increased in the resistant subline. See text.
spots representing tubulin on 2D gels of proteins from the treated cells assisted in identification of those peptides. Identity of a-and/3-tubulin spots on the 2D gels was confirmed by co-electrophoresis of pig brain tubulin, prepared according to Shelanski et al. (41) , with labeled CHL cell protein.
In Vitro Translation: Procedures for polysome isolation, mRNA purification, and cell-free protein synthesis were carried out as described by Melera et al. (8) .
RESULTS
Resistance and Cross-resistance of Cell Lines Selected with VCR
As part of an ongoing investigation to uncover genetic mechanisms of resistance to a variety of cancer chemotherapeutic agents, we independently selected two VCR-resistant sublines, DC-3F/VCRd and DC-3F/VCRm, from DC-3F, one VCR-resistant line from the mouse tumor line, MAZ, and a fourth subline from the cloned human neuroblastoma line, SH-SY5Y. Levels of resistance of drug-treated cells range from 500-to 4,000-fold (Table I) .
To assess the presence and extent of the multidrug-resistant phenotype in cell lines selected with the Vinca alkaloid, we carried out cross-resistance assays on the 650-fold VCRresistant DC-3F/VCRd CHL cells and, to a more limited extent, on VCR-resistant mouse and human cells. In general, degree of cross-resistance of DC-3F/VCRd cells is greatest for drugs known to affect microtubule polymerization; indeed, the VCR-resistant cells show reduced sensitivity to all antimitotic drugs and experimental analogs tested (Table II) . DC-3F/VCRd cells are cross-resistant, to a lesser extent, to a variety of other agents. The low levels of cross-resistance to 6-thioguanine, arabinosylcytosine, methotrexate, and 1,3-bis(2-chloroethyl)-l-nitrosourea are probably not significant (31) . The mouse and human VCR-resistant cell lines, like CHL cell sublines, are cross-resistant to actinomycin D, exhibiting increases of 571-and 200-fold, respectively, as compared with controls.
Chromosomal Abnormalities Characterizing VCRresistant Cell Lines
CHINESE HAMSTER SUBLINES:
Routine karyotypic analysis of the 650-fold resistant subline, DC-3F/VCRd, revealed the presence of an HSR (Fig. 1 ). HSRs were subsequently observed in cells of all DC-3F/VCRd sublines (DC-3F/VCRd-1, DC-3F/VCRd-5, DC-3F/VCRd-5L). The HSR is located interstitially on a marker chromosome and comprises, on average, 2.7% of the total chromosome length in a cell. It stains uniformly although somewhat more intensely than a typical HSR in antifolate-resistant CHL cells ( 1, 2, 35) . The HSR of DC-3F/VCRd cells commences and completes DNA replication early in S-phase as shown by [3H]thymidinelabeling studies (Fig. 2, a- 
c).
The labeling studies also demonstrated that the segment of the marker chromosome arm distal to and including an apparent secondary constriction region ( Fig. 1 ) is clearly latereplicating (Fig. 2c ). This segment thus most probably comprises the distal half of the long arm of an X chromosome (bands Xq21-Xqter) that, in normal cells, stains similarly to an HSR. The origins of the grey band proximal to Xq21 (the secondary constriction region) and of a wide, palely staining band between the HSR and a seemingly normal entire chromosome 8 are ambiguous. The marker chromosome thus comprises a t(X;8;HSR;?)(8qter---,8pI9::?::HSR::?::Xq21---~ Xqter).
Chromosomal analysis of the second, independently-derived VCR-resistant CHL cell line, DC-3F/VCRm, revealed the presence of an ABR, a long, obscurely banded region comprising 3.8% of the total chromosome length, on a pre- sumptive chromosome 10p21 (Fig. 1) . In these cells, both chromosome 8 homologues are normal. Moreover, although the single X chromosome has been rearranged distal to the secondary constriction region of the long arm, the region between the centromere and band Xq22 is normal. Thus, there appears to be no correspondence between the locations of the HSR in DC-3F/VCRd cells and the ABR in DC-3F/ VCRm cells. Control DC-3F cells and the actinomycin Dand daunorubicin-resistant lines DC-3F/AD X and DC-3F/ DM XX, also used as controls in these studies, contain no anomalous regions (nor DMs). Even the 50,000-fold resistant DC-3F/AD XC cells have no chromosomal regions with abnormal band patterns corresponding to the ABR of DC-3F/VCRm. Both of the VCR-resistant CHL sublines contain numerous structurally altered chromosomes, including two that are common to all DC-3F sublines (Fig. 1) . DC-3F/VCRd sublines also contain 2-3 small supernumerary chromosomes. Whether these small, abnormal chromosomes or unidentifiable segments present on rearranged chromosomes represent ABRs is an open question. MOUSE TUMOR LINES: Drug-sensitive MAZ cells have a modal chromosome number of 67-70 and contain an average of 24 DMs per cell in 65% of cells. DM number and frequency increased markedly after exposure to VCR; 100% of MAZ/VCR cells, selected at 20 •g/ml VCR and ~4,000-fold resistant to drug (Table I) , are characterized by an average of 183 very small DMs near the resolving limit of the light microscope (Fig. 2d) . Of 100 cells examined, no cell contained <50 DMs, and two-thirds of the cells had >100 DMs per cell. Resistant cells do not exhibit long HSRs or obvious ABRs; short HSRs or ABRs, however, could be present but not as yet identified owing to the type and extent of rearrangement characteristic of MAZ cells.
HUMAN NEUROBLASTOMA CELL LINES: A VCR-resistant subline was also selected over a 7-yr period from the human neuroblastoma line, SH-SY5Y. Unlike most human neuroblastoma cell lines described so far (43), hyperdiploid SH-SY5Y cells and the SK-N-SH line from which the thricecloned subline was isolated have never been observed to contain HSRs or DMs (34) . The 1,300-fold resistant cells, however, are characterized by an average of 40 DMs per cell in 100% of cells (Fig. 2e) ; no cell contains <10 DMs, 30% of cells have >50, and 6% have >100 DMs.
Protein Changes in VCR-resistant CHL Cells
A possible protein product of amplified genes in VCRresistant cells is a protein we have designated V19 (24) . Vl9 is seen on 2D gels of cytosol proteins of DC-3F/VCRd-5 cells (Fig. 3) and of the more highly resistant DC-3F/VCRd-5L cells. Further, DC-3F/VCRm cells also synthesize V19, although in lesser amounts (data not shown). The relative abundance of V19 seen on these gels reflects an increased abundance of V 19 mRNA in the VCR-resistant cells. 2D gels of translation products of polysomal mRNA from DC-3F/ VCRd-5L cells show a prominent V19 spot (Fig. 4b ) compared with control (Fig. 4a) , whereas DC-3F/VCRm cell material had lower levels of V19-specific mRNA (data not shown). Two other proteins are also overproduced in DC-3F/ VCRd-5 cells: V61 (Mr 61,000; pI = 7.2) (Fig. 3) and V92 (Mr 92,000; pI = 7.1) (not shown). V61, however, is not seen on gels from DC-3F/VCRm, and neither V61 nor V92 is identifiable on gels of translation products of DC-3F/VCRd-5L polysomal mRNA (Fig. 4) . V19 is also readily identified on 2D gels of MAZ/VCR cell proteins (Fig. 5) ; V61 and V92 are not seen on MAZ/VCR gels. In earlier studies, cytosol polymerized microtubule pellet, and V19 synthesis is not altered by colchicine treatment (data not shown).
Reversion of Resistance and Loss of HSR, DMs, and V19 Expression
To assess the stability of the VCR-resistant phenotype in absence of drug selection pressure, we cloned the DC-3F/ VCRd subline in the presence of 5 #g/ml VCR. We then transferred two clonally derived sublines, DC-3F/VCRd-1 and DC-3F/VCRd-5, to drug-free medium and redesignated them DC-3F/VCRd-l-U and DC-3F/VCRd-5-U (Table I) . Levels of resistance declined between the first two assays done after 3 and 9 wk in the absence of VCR (Table III) . During the first 4 mo of the 2t/2-yr experimental period, the rate of decrease was more rapid for DC-3F/VCRd-l-U than for DC-3F/VCRd-5-U cells (t~/2 = 60 and 120 d, respectively). After an initial decline, resistance of DC-3F/VCRd-1-U cells stabilized for 8 mo at an intermediate level, and again declined rapidly until reaching control level (Table III) . In contrast, the resistance level of DC-3F/VCRd-5-U cells decreased pro- Fig. 3 . The numbers on the photographs are for orientation purposes. V19 and its expected location in MAZ are circled. Area of this detail is enclosed by dotted lines in Fig. 3 .
proteins of the VCR-sensitive and -resistant hamster and mouse cell lines were examined by sodium dodecyl PAGE. In addition to Vl9, two other protein species (Mr 43,000 and 32,000-35,000) were present in increased amounts in resistant cells (data not shown). These two proteins are not consistently identifiable on 2D gels but are of potential future interest.
The high degree of cross-resistance of DC-3F/VCRd cells to various antimitotic agents (Table II) and studies in other laboratories (27) (28) (29) (30) suggested the possibility that tubulin protein was overproduced or altered in the resistant cells. Analysis by 2D gel electrophoresis of polymerization-competent tubulin (Fig. 6) or of unpolymerized tubulin in absence and presence of colchicine (Fig. 7) showed no evidence for either overproduction or mutation of a-or/~-tubulin in VCRresistant CHL cells. V 19 does not copolymerize with tubulin; it remains in the supernatant material above the in vitro (30) and soluble material containing 5-6 x 10 s cpm per aliquot was applied to first dimension gels. Procedures for these experiments were described by Ben-Ze'ev et al. (42) as stated in Materials and Methods. Numbers are used for orientation purposes. Spot g is actin, a is ~x-tubulin and /3 is /3-tubulin. Two forms of c~-tubulin (c~1 and ~2) are evident in DC-3F untreated gels and are not observed on the gels of colchicinetreated cell samples, a-Tubulin was frequently not observed or was seen as an indistinct spot on DC-3F/VCRd-5L gels. mosome band cannot be determined at this time. The revertant cells, however, retained the structurally rearranged chromosomes 1, 6, and 7 that are characteristic of the drugresistant progenitors but not seen in drug-sensitive cells. The presence of these marker chromosomes and of the 8-Xq chromosome indicated unequivocally that the revertant cells, even those that had completely lost resistance, were derived from the resistant cells and were not cell contaminants. Decrease in resistance and in HSR length in DC-3F/VCRd-5-U cells was also accompanied by a decrease in V 19 synthesis (Fig. 3 c) and a decreased concentration of V I9 mRNA (Fig.  4 c) . The amount of the other two proteins, V61 (Fig. 3 c) and V92, remained elevated, even in cells with only a 33-fold residual resistance level.
TABLE III
Concomitant Decrease in Resistance to Vincristine and in HSR Length in Two Clones Isolated from the DC-3F/VCRd Cell Line
Both DM-containing VCR-resistant sublines, mouse MAZ/ VCR and human SH-SY5Y/VCR, also underwent phenotypic reversion when grown in drug-free medium. Decline in resistance was rapid for both lines, with tl/2 = 10 d for MAZ/ VCR-U and 30 d for the more slowly growing human SH-SY5Y/VCR-U cells. Resistance of the MAZ/VCR-U subline stabilized at a level fourfold higher than that of control MAZ cells (Table IV) after -5 mo and remained at that level for another 9 mo, at which time the experiment was terminated. Decrease in resistance was paralleled by a decrease in DM number and frequency (Table IV ; Fig. 9 ) and by a decrease in synthesis of V19 (Fig. 9) . The VI9 spot, as seen in Fig. 5 b, is absent in MAZ/VCR-U protein gels (not shown).
DISCUSSION
Resistance and cross-resistance patterns observed for DC-3F/ VCRd cells, in the present study, differ from those previously reported for actinomycin D-and daunorubicin-resistant CHL cells (22, 44) . The levels of resistance or cross-resistance of DC-3F/VCRd cells to actinomycin D and daunorubicin are low compared with VCR itself and other antimitotics such as vindesine and colchicine, suggesting that there is a resistance mechanism in these cells involving microtubule function alteration. Actinomycin D-resistant (DC-3F/AD X) and daunorubicin-resistant (DC-3F/DM XX) cells, on the other hand, show relatively high levels of cross-resistance to vincristine and other alkaloids. This suggests that drug exclusion plays a more important role in expression of resistance in the antibiotic-resistant cells. In general, all of the cross-resistance gressively for ~ 11/2 yr, ultimately stabilizing at a level 33-fold higher than that of control DC-3F cells (Table III) .
Decrease in resistance was paralleled by a decrease in the mean length of the HSR (Table III) . At any one time point during the reversion process, there was considerable heterogeneity among cells with respect to HSR length (Fig. 8) . However, diminution in length of the HSR was not associated with obvious chromosomal breakage or rearrangement. In nearly all cells examined, the composition of the marker chromosome, i.e., 8-HSR-Xq, remained constant; only the length of the interstitial HSR was altered. After 28 mo, HSRs had diminished in size to the approximate width of a normal chromosome band, situated between the secondary constriction (band Xq21) of the X chromosome and the elongated, palely staining 8p+ region. Whether the remaining band represents residual HSR material or a normal Xql 8 chro- VCR-resistant CHL cells share many of the characteristics of HSR-and ABR-containing antifolate-resistant sublines also derived from control DC-3F cells: (a) as in highly resistant methotrexate-and methasquin-resistant DC-3F cells (1, 35) and in numerous other cell lines selected with methotrexate (11-13, 45, 46) and known to contain amplified genes coding for DHFR, DC-3F/VCRd and DC-3F/VCRd-5L cells with the highest level of VCR resistance contain an HSR on a single chromosome; (b) the HSRs of the VCR-resistant cells stain homogeneously but somewhat more darkly than those typifying antifolate-resistant cells; they comprise ~3% of the total chromosome length (22) compared with 4-5% for the antifolate-resistant cells (35) ; (c) DNA of the HSR characterizing both methotrexate-and VCR-resistant cells is replicated synchronously and starts replication early during the S-period (1) (Fig. 2) , consistent with the possibility that it is a transcriptionally active region; (d) like antifolate-resistant CHL sublines with low levels of resistance (23, 25) , a second, independently derived VCR-resistant subline, DC-3F/VCRm, with a slightly lower level of resistance, has an ABR; (e) when clonally derived sublines of DC-3F/VCRd were grown in drug-free medium, there was a decline in resistance and mean length of the HSR (Table III) , as previously demonstrated for antifolate-resistant DC-3F sublines (35) .
The VCR-resistant CHL cell system differs from the antifolate-resistant system in the chromosomal location of the HSR or ABR. In the latter, the regions are preferentially (but not always) located on a particular arm of chromosome 2 (1, 11, 35) . In the VCR-resistant cells, chromosome 2 is not involved. However, we have only two independent VCRresistant sublines and thus cannot infer the permanent location of a putatively amplified gene.
There are also clear similarities between the VCR-resistant mouse MAZ/VCR subline and the previously described antifolate-resistant subline MAZ/A/MQ (19) , both derived from the same control cell line MAZ. The 4,000-fold resistant MAZ/VCR cells contain high and variable numbers of DMs (an average of 183 per cell). The 50,000-fold resistant MAZ/ A/MQ cells average >300 DMs per cell (19) ; the association between the presence of DMs and amplification of the DHFRencoding gene is well-established ( 15, 18, 20, 21) . When each of the lines was maintained in the absence of selective agent, there was a rapidly initiated and rapidly progressive loss of resistance and mean number of DMs per cell (Table IV) (l 9) .
One important attribute that may distinguish gene amplification-associated drug resistance from resistance developing as a consequence of other genotypic alterations, e.g., base substitution or deletion, is instability of the resistant phenotype in the absence of drug selection pressure (19) . In all four cell lines tested for stability of resistance, two of the lines derived from mass cell populations and two isolated as clonal subpopulations, resistance decreased markedly during growth in drug-free medium. For two cell lines, sensitivity to VCR returned to near-control levels, suggesting that in these lines, DC-3F/VCRd-I-U and SH-SY5Y/VCR-U, amplification of one or several genes may be the major mechanism of resistance. In DC-3F/VCRd-5-U cells, however, resistance stabilized at a level 30-fold higher than that of the controls. Whether this residual resistance indicates the operation of a second resistance mechanism not associated with gene amplification or presence of a small number of amplified genes integrated into one or more chromosomally undetectable sites, an apparently stable arrangement in antifolate resistant cells (19) , is unknown.
One candidate protein product of the amplified genes is V19. This previously reported (24) ReceivedJbr publication 10 July 1984, and in revised form 22 October 1984. 
